US9266891, III-51 | 1610045-36-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: US9266891, III-51
• 英文别名: 3-methyl-6-[6-morpholin-4-yl-1-(pyridin-3-ylmethyl)imidazo[4,5-c]pyridin-2-yl]-N-[(3R)-oxolan-3-yl]-[1,2,4]triazolo[4,3-a]pyrazin-8-amine
• CAS: 1610045-36-7
• 化学式: C₂₆H₂₈N₁₀O₂
• 分子量: 512.574
• InChiKey: VSKQFDSORJPDSV-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• TRIAZOLOPYRAZINE
  申请人：ENGELHARDT Harald

  公开号：US20140142098A1

  公开（公告）日：2014-05-22

  Disclosed are compounds of the formula (I) wherein the groups R 1 to R 3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

  公开的是具有以下式（I）的化合物，其中基团R1至R3具有权利要求和说明书中给出的含义。本发明的化合物适用于治疗由细胞过度或异常增殖所特征化的疾病，包含这些化合物的制药制剂以及它们作为药物的用途。
• SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS BRD4 INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160129001A1

  公开（公告）日：2016-05-12

  Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R 1 to R 3 have the meanings given in the specification.

  使用化合物(I)治疗AML和MM的方法，其中R1至R3基团的含义如规范中所述。
• Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10328074B2

  公开（公告）日：2019-06-25

  Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.

  通过施用式 (I) 化合物治疗急性髓细胞白血病和 MM 的方法 其中基团 R1 至 R3 的含义见说明书。
• Triazolopyrazine
  申请人：Boehringer Ingelheim International GmbH

  公开号：US11077107B2

  公开（公告）日：2021-08-03

  Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

  公开了式 (I) 的化合物 其中基团 R1 至 R3 具有权利要求和说明书中给出的含义。本发明的化合物适用于治疗以细胞过度增殖或异常增殖为特征的疾病，含有此类化合物的药物制剂及其作为药物的用途。
• TRIAZOLOPYRAZINES AS BRD4 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2925761B1

  公开（公告）日：2017-07-05